Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Indications and Usage Saxenda (liraglutide) injection 3 mg is indicated in combination with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with body weight greater than 60kg and obesity Adults with overweight in the presence of at least one weight related comorbid condition Limitations of Use Saxenda contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist The safety and effectiveness of Saxenda in pediatric patients with type 2 diabetes have not been established References 1
Routine cardiovascular risk assessments and timely implementation of GLP-1RAs and SGLT2 inhibitors are also essential for reducing the adverse CVEs in patients with NAFLD and type 2 diabetes
NSL literature pointer PMID 20439816 L-Carnitine laboratory index [PMID: 20439816] National Science Labs indexing note for PMID 20439816: review the PubMed methods, models, and limitations before citing
This is, however, a potentially concerning effect when it comes to oral medications
